Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners

The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…

Mark C. Schneyer net worth and biography

Mark Schneyer Biography and Net Worth

CFO of ACADIA Pharmaceuticals

Mark Schneyer is our Executive Vice President, Chief Financial Officer, and he has been with Acadia since May 2020.

Prior to his promotion to CFO in December 2021, he served as Senior Vice President, Business Development, Chief Business Officer and Interim Chief Financial Officer.

Mr. Schneyer joined us from Pfizer Inc. where he most recently was Vice President, Business Development, for the Upjohn Division. Mr. Schneyer joined Pfizer’s Worldwide Business Development organization in 2011 and served in various business development positions of increasing responsibility. While at Pfizer, he led multiple strategic transactions, including licensing agreements, product acquisitions and divestitures, strategic collaborations, and company acquisitions.

Prior to Pfizer, he was an investment banker at Lazard and advised boards of directors and senior management teams in the healthcare sector. Mr. Schneyer earned a Bachelor of Science in Economics with a Concentration in Finance from the Wharton School of Business at the University of Pennsylvania.

What is Mark C. Schneyer's net worth?: The estimated net worth of Mark C. Schneyer is at least $867,223.54 as of November 19th, 2024. Mr. Schneyer owns 53,302 shares of ACADIA Pharmaceuticals stock worth more than $867,224 as of November 21st. This net worth evaluation does not reflect any other investments that Mr. Schneyer may own. Additionally, Mr. Schneyer receives a salary of $701,030.00 as CFO at ACADIA Pharmaceuticals. Learn More about Mark C. Schneyer's net worth.
How old is Mark C. Schneyer?: Mr. Schneyer is currently 49 years old. There are 5 older executives and no younger executives at ACADIA Pharmaceuticals. The oldest executive at ACADIA Pharmaceuticals is Mr. Stephen R. Davis J.D., President, CEO & Director, who is 63 years old. Learn More on Mark C. Schneyer's age.
What is Mark C. Schneyer's salary?: As the CFO of ACADIA Pharmaceuticals Inc., Mr. Schneyer earns $701,030.00 per year. There are 2 executives that earn more than Mr. Schneyer. The highest earning executive at ACADIA Pharmaceuticals is Mr. Stephen R. Davis J.D., President, CEO & Director, who commands a salary of $1,460,000.00 per year. Learn More on Mark C. Schneyer's salary.
How do I contact Mark C. Schneyer?: The corporate mailing address for Mr. Schneyer and other ACADIA Pharmaceuticals executives is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. ACADIA Pharmaceuticals can also be reached via phone at (858) 558-2871 and via email at [email protected]. Learn More on Mark C. Schneyer's contact information.
Has Mark C. Schneyer been buying or selling shares of ACADIA Pharmaceuticals?: Within the last three months, Mark C. Schneyer has sold $172,453.79 of ACADIA Pharmaceuticals stock. Most recently, Mark C. Schneyer sold 10,259 shares of the business's stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $16.81, for a transaction totalling $172,453.79. Following the completion of the sale, the chief financial officer now directly owns 53,302 shares of the company's stock, valued at $896,006.62. Learn More on Mark C. Schneyer's trading history.
Who are ACADIA Pharmaceuticals' active insiders?: ACADIA Pharmaceuticals' insider roster includes Laura Brege (Director), Stephen Davis (CEO), James Kihara (Insider), Austin Kim (EVP), Elena Ridloff (CFO), Mark Schneyer (CFO), Srdjan Stankovic (President), and Brendan Teehan (COO). Learn More on ACADIA Pharmaceuticals' active insiders.
Are insiders buying or selling shares of ACADIA Pharmaceuticals?: During the last year, insiders at the biopharmaceutical company sold shares 26 times. They sold a total of 172,819 shares worth more than $3,042,092.93. The most recent insider tranaction occured on November, 19th when COO Brendan Teehan sold 10,329 shares worth more than $173,630.49. Insiders at ACADIA Pharmaceuticals own 28.3% of the company. Learn More about insider trades at ACADIA Pharmaceuticals.
Information on this page was last updated on 11/19/2024.

Mark C. Schneyer Insider Trading History at ACADIA Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/19/2024	Sell	10,259	$16.81	$172,453.79	53,302
8/19/2024	Sell	9,733	$15.28	$148,720.24	43,735
6/10/2024	Sell	975	$14.79	$14,420.25	34,564
5/2/2024	Sell	3,503	$16.94	$59,340.82	32,053
4/8/2024	Sell	2,716	$17.87	$48,534.92	28,742
3/27/2024	Sell	5,434	$17.90	$97,268.60	26,183
2/26/2024	Sell	772	$24.67	$19,045.24	21,067
11/20/2023	Sell	5,108	$22.64	$115,645.12	20,486
8/21/2023	Sell	10,000	$29.00	$290,000.00	15,682
6/8/2023	Sell	974	$25.02	$24,369.48	22,824
5/17/2023	Sell	15,310	$22.50	$344,475.00	21,905
4/6/2023	Sell	1,916	$18.16	$34,794.56	7,477
2/24/2023	Sell	577	$18.78	$10,836.06	4,118
6/9/2022	Sell	653	$17.91	$11,695.23	3,342

Mark C. Schneyer Buying and Selling Activity at ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Company Overview

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Today's Range

Now: $16.27

$16.05

$16.39

50 Day Range

MA: $15.61

$14.29

$18.27

2 Week Range

Now: $16.27

$14.15

$32.59

Volume

1,087,297 shs

Average Volume

1,679,200 shs

Market Capitalization

$2.71 billion

P/E Ratio

20.86

Dividend Yield

N/A

Beta

0.38

Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners

From Colonial Metals | Ad

Claim your FREE 2024 Gold Guide

Mark Schneyer Biography and Net Worth

What is Mark C. Schneyer's net worth?

How old is Mark C. Schneyer?

What is Mark C. Schneyer's salary?

How do I contact Mark C. Schneyer?

Has Mark C. Schneyer been buying or selling shares of ACADIA Pharmaceuticals?

Who are ACADIA Pharmaceuticals' active insiders?

Are insiders buying or selling shares of ACADIA Pharmaceuticals?